BioCentury
ARTICLE | Financial News

China's Ally Bridge adds European companies to portfolio

February 24, 2017 1:50 AM UTC

Hong Kong's Ally Bridge Group continued to find deals in Europe, announcing it has added Austria's Nabriva Therapeutics AG (NASDAQ:NBRV) and Switzerland's Galenica Ltd. (SIX:GALN) to its portfolio. Ally Bridge declined to disclose specifics but said the combined amount of the investments was "in several tens of millions."

Nabriva is in the Phase III LEAP trial with both oral and IV lefamulin (BC-3781) antibiotic formulations to treat moderate to severe community-acquired bacterial pneumonia (CABP), with data anticipated in 3Q17...